SaI [Sa I, Sarcoma I] (ATCC® CRL-2543)

Organism: Mus musculus, mouse  /  Cell Type: dibenzanthracene induced  /  Disease: fibrosarcoma, malignant

Permits and Restrictions

View Permits

Organism Mus musculus, mouse
Cell Type dibenzanthracene induced
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Disease fibrosarcoma, malignant
Applications
It can be used in immunology and cancer studies.
The cells may be used for transfection studies.
The cell line can be used as a model for testing immunotherapy protocols.
Storage Conditions liquid nitrogen vapor phase
Derivation
The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene
Clinical Data
The cell line can be used as a model for testing immunotherapy protocols.
Antigen Expression
MHC class I +; MHC class II -
H-2a
Genes Expressed
MHC class I +; MHC class II -,H-2a
Tumorigenic Yes
Effects
Yes, grows as ascites in A/Jax mice but not in C57BL/6K mice
Comments
The Sarcoma I tumor originated in 1947 in a mouse that had been treated with dibenzanthracene
The tumor grows progressively in the A/Jax subline of the Strong A mouse and kills 100% of the animals. In contrast, mice of the resistant C57BL/6K strain reject the tumor in about 100% of the cases.
The SaI variant (ATCC CRL-2543) grows as an ascites tumor when inoculated intraperitoneally, while the SaI/N variant grows as a solid tumor when inoculated subcutaneously
The cell line can be used as a model for testing immunotherapy protocols. It can be used in immunology and cancer studies. The cells may be used for transfection studies.
Complete Growth Medium The base medium for this cell line is ATCC-formulated Iscove's Modified Dulbecco's Medium, Catalog No. 30-2005. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing
Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 5 X 10(5) viable cells/ml.
Interval: Maintain cell density between 5 X 10(5) and 2 X 10(6) viable cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Name of Depositor S Ostrand-Rosenberg
References

Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917

Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962.

Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
References

Baskar S, et al. Major histocompatibility complex class II+B7-1+ tumor cells are potent vaccines for stimulating tumor rejection in tumor-bearing mice. J. Exp. Med. 181: 619-629, 1995. PubMed: 7836917

Baker P, et al. Mechanisms of tumor homograft rejection: The behavior of Sarcoma I ascites tumor in the A/Jax and the C57BL/6K mouse. Ann. N.Y. Acad. Sci. 101: 46-63, 1962.

Dunham LJ, Stewart HL. A survey of transplantable and transmissible animal tumors. J. Natl. Cancer Inst. 13: 1299-1377, 1953. PubMed: 13035452